Does Blue Cross Blue Shield of Michigan Cover Dupixent?

What Is Dupixent and Why Does Coverage Get Complicated?

Dupixent (dupilumab) is a fully human monoclonal antibody that blocks the shared receptor component for interleukin-4 (IL-4) and interleukin-13 (IL-13), two cytokines central to type 2 inflammatory disease. The FDA has granted it approvals across six distinct conditions since 2017, making it one of the broadest-label biologics on the market. Because it carries a list price near $38,000 per year, every major insurer including BCBSM applies strict utilization-management controls before paying for it.

The Six FDA-Approved Indications

Each approved indication has its own clinical criteria, and BCBSM's prior authorization forms ask about all of them separately. The current FDA-approved uses are:

• Moderate-to-severe atopic dermatitis (age 6 months and older)
• Moderate-to-severe asthma with an eosinophilic phenotype or oral corticosteroid-dependent asthma (age 6 and older)
• Chronic rhinosinusitis with nasal polyps (CRSwNP, age 18 and older)
• Eosinophilic esophagitis (EoE, age 12 and older, weight at least 40 kg)
• Prurigo nodularis (age 18 and older)
• COPD with a type 2 inflammatory phenotype (FEV1/FVC <0.7 post-bronchodilator, blood eosinophils ≥300 cells/µL)

The FDA's prescribing information for dupilumab is the foundational document insurers reference when writing their medical policies. You can review it at the FDA label for Dupixent.

Why Specialty Tier Placement Matters

BCBSM places Dupixent on its specialty tier across most plan designs. Specialty-tier cost sharing in Michigan commercial plans commonly runs 20-33% coinsurance after the deductible, which on a $38,000 annual drug translates to $7,600-$12,500 out-of-pocket before any assistance. That math is why understanding your specific plan's specialty tier cap and the Dupixent MyWay program matters before filling the first prescription.

How BCBSM Prior Authorization Works for Dupixent

Prior authorization (PA) is not optional. The Blue Cross Blue Shield Association publishes national medical policies that member plans adopt, and dupilumab's utilization-management requirements are among the most detailed in any specialty formulary. Your prescribing physician submits the PA request, but understanding the process helps you ensure it is complete.

Required Clinical Documentation

BCBSM PA reviewers typically require the chart to contain:

1. A confirmed diagnosis matching an FDA-approved indication, documented by a board-certified dermatologist, allergist/immunologist, pulmonologist, or gastroenterologist depending on the condition.
2. Evidence that the disease is moderate-to-severe. For atopic dermatitis, this means an Investigator Global Assessment (IGA) score of 3-4 or a body-surface-area involvement typically above 10%, consistent with the criteria used in the SOLO 1 and SOLO 2 trials.
3. Documentation of step therapy failure or contraindication (see section below).
4. Current weight (required for pediatric dosing calculations).
5. Absence of active helminth infection, per the FDA label.

The American Academy of Dermatology's 2023 guidelines for atopic dermatitis describe moderate-to-severe disease thresholds in detail and are cited by many payers in their coverage criteria. Review that document at AAD guidelines via the Journal of the American Academy of Dermatology [1].

Step Therapy: What You Must Try First

For atopic dermatitis, BCBSM typically requires documented failure of at least one or two conventional systemic agents. Agents that satisfy step therapy requirements most commonly include:

• Topical corticosteroids (mid-to-high potency, used for at least 4-8 weeks)
• Topical calcineurin inhibitors (tacrolimus 0.1%, pimecrolimus 1%)
• Cyclosporine (off-label in the US but accepted by many plans)
• Methotrexate or azathioprine for at least 3 months

Failure can mean inadequate response, a clinically significant adverse effect, or a documented contraindication. Your physician must be specific: "patient tried triamcinolone 0.1% cream for 8 weeks with less than 25% reduction in EASI score" is more approvable than "topical steroids failed."

For asthma, step therapy documentation typically requires adherence to high-dose inhaled corticosteroid plus a long-acting beta-agonist (ICS/LABA) for at least 3 months, evidence of poor control (ACT score <16 or FEV1 <80% predicted), and blood eosinophil count reported (usually ≥150 cells/µL for most commercial plans, ≥300 cells/µL for some). GINA 2024 guidelines provide the clinical benchmarks Michigan payers reference most often; see GINA 2024 on the NHLBI/NIH site [2].

PA Decision Timelines Under Michigan Law

Michigan's Utilization Review Act requires commercial insurers to issue standard PA decisions within 72 hours of receiving a complete request, and expedited decisions within 24 hours when the standard timeline could seriously jeopardize the member's health. If BCBSM does not meet these timelines, you can file a complaint with the Michigan Department of Insurance and Financial Services (DIFS).

What the Clinical Trial Evidence Shows About Dupixent

Payers write coverage criteria based on the same trial data that supported FDA approval. Knowing these numbers helps your physician document in language that matches insurer expectations.

Atopic Dermatitis: SOLO 1 and SOLO 2

The key Phase 3 trials SOLO 1 (N=671) and SOLO 2 (N=708) showed that dupilumab 300 mg every two weeks produced an IGA 0 or 1 ("clear" or "almost clear") response in 37-38% of patients at week 16, compared with 10% for placebo (P<0.001) [3]. A co-primary endpoint, EASI-75 (75% or greater reduction in Eczema Area and Severity Index), was achieved by 51-52% of dupilumab patients versus 15-16% on placebo [3]. These numbers are the baseline BCBSM reviewers use when evaluating whether a patient's disease is truly inadequately controlled on prior therapy.

The SOLO 1 and SOLO 2 full publication in the New England Journal of Medicine is a primary source for coverage-criteria language [3].

Asthma: LIBERTY ASTHMA QUEST

In the LIBERTY ASTHMA QUEST trial (N=1,902), dupilumab 200 mg every two weeks reduced annualized severe exacerbation rates by 47.7% compared with placebo in patients with baseline blood eosinophils ≥150 cells/µL (P<0.001) [4]. Patients with eosinophils ≥300 cells/µL showed a 65.8% reduction in exacerbations [4]. Pre-bronchodilator FEV1 improved by 0.32 L over 52 weeks versus 0.18 L with placebo in that high-eosinophil group [4]. The QUEST trial in the Lancet provides the citation BCBSM reviewers will recognize [4].

CRSwNP: SINUS-24 and SINUS-52

The SINUS-24 (N=276) and SINUS-52 (N=448) trials demonstrated statistically significant reductions in nasal polyp score and nasal congestion score with dupilumab 300 mg every two weeks versus placebo at weeks 24 and 52 [5]. Mean nasal polyp score decreased by 2.06 points from baseline in the dupilumab arm versus 0.19 with placebo in SINUS-52 (P<0.001) [5]. See the SINUS trial publication via PubMed [5].

Prurigo Nodularis: LIBERTY-PN PRIME and PRIME2

In PRIME (N=151) and PRIME2 (N=160), dupilumab 300 mg every two weeks achieved a clinically meaningful reduction in itch intensity (Peak Pruritus NRS improvement ≥4 points) in 60% of patients at week 24 versus 18% with placebo in PRIME (P<0.001) [6]. The PRIME trial on PubMed anchors the prurigo nodularis coverage criteria [6].

EoE: PART A of the EoE Trial Program

The EoE Phase 3 trial Part A (N=81) showed that 42% of patients treated with dupilumab 300 mg weekly achieved histologic remission (peak esophageal eosinophil count <6/hpf) at week 24 versus 3% with placebo (P<0.001) [7]. Full publication available at PubMed for the EoE dupilumab trial [7].

Cost and Copay Assistance Options for BCBSM Members

Even with approval, cost sharing on specialty biologics can be prohibitive. Multiple programs address this, and which ones apply depends entirely on your insurance type.

Dupixent MyWay Copay Card (Commercial Plans Only)

Regeneron and Sanofi operate the Dupixent MyWay program, which offers eligible commercially insured patients copay assistance that can reduce their out-of-pocket cost to $0 per month for qualifying plans. Patients with government-funded insurance (Medicare Part D, Medicaid, CHIP, or any federal employee plan) are not eligible. BCBSM commercial plan members should enroll at dupixent.com or by calling 1-844-DUPIXENT before their first fill. Income limits do not apply to the copay card program.

Patient Assistance Program for Uninsured or Underinsured Patients

For patients without coverage or who are denied, the Dupixent MyWay Patient Assistance Program provides free drug to qualifying low-income patients. Income thresholds and household size determine eligibility. This is separate from the copay card.

Medicare Extra Help / Low-Income Subsidy

Medicare Part D members who fall below 150% of the federal poverty level may qualify for the Extra Help program, which caps drug costs significantly. The Social Security Administration administers Extra Help applications. See SSA Extra Help information on ssa.gov or the CMS overview at cms.gov [8].

Michigan Medicaid (Healthy Michigan Plan)

Michigan Medicaid covers dupilumab for Medicaid-eligible patients who meet medical criteria. The Healthy Michigan Plan, Michigan's Medicaid expansion program, covers biologics under its preferred drug list (PDL). The Michigan Department of Health and Human Services updates its PDL quarterly. For current PDL status, see Michigan DHHS pharmacy information at michigan.gov [9].

What to Do If BCBSM Denies Your Dupixent PA

Denial is not the end of the road. A structured appeal process exists, and published data from the Kaiser Family Foundation suggest that 40-60% of denied specialty drug prior authorizations are overturned on appeal when the appeal includes additional clinical documentation.

Step 1: Request the Denial Letter and Clinical Rationale

BCBSM is required to provide a written explanation of why the PA was denied, including the specific clinical criteria the request did not meet. Get this in writing. It tells you exactly what to address in the appeal.

Step 2: File an Internal (Level 1) Appeal

Your physician or their office can file an internal appeal within 180 days of the denial notice for most BCBSM commercial plans. The appeal should include:

• A detailed letter of medical necessity from the prescribing physician referencing published guidelines (AAD, GINA, AGA as applicable)
• Peer-reviewed literature supporting use in your specific clinical scenario
• Any updated lab values, IGA scores, EASI scores, spirometry results, or endoscopy findings
• Documentation of all prior therapies tried, doses used, duration, and the specific reason each was stopped

The American Academy of Allergy, Asthma and Immunology publishes position statements on biologic coverage that physicians commonly include in appeal packages. See AAAAI position statements at aaaai.org [10].

Step 3: Peer-to-Peer Review

Your physician can request a peer-to-peer call with the BCBSM medical reviewer who issued the denial. Success rates improve when a board-certified specialist in the relevant discipline (dermatologist, allergist, pulmonologist, or gastroenterologist) conducts this call and can cite trial data by name and N.

Step 4: External Independent Review

If the internal appeal is denied, Michigan law grants members the right to an external independent review (IRO) through the Michigan Department of Insurance and Financial Services. The IRO decision is binding on the insurer. File your IRO request through DIFS at michigan.gov/difs [11].

Step 5: Expedited Review for Urgent Cases

If waiting for the standard appeal timeline would seriously jeopardize your health, request an expedited appeal. BCBSM must issue an expedited internal appeal decision within 72 hours. Expedited IRO decisions are required within 36 hours under Michigan law.

How Physicians Can Write a Stronger PA to Avoid Denial

The PA submission quality is the single biggest determinant of first-pass approval. Incomplete submissions are the most common reason for denial, not clinical ineligibility.

Matching Documentation to BCBSM's Criteria Language

BCBSM's medical policies for specialty biologics are publicly accessible through the Blue Cross Blue Shield Association's medical policy portal. Your physician's office should pull the current policy, read the exact criteria language, and write the PA narrative to address each bullet point explicitly. Vague language like "patient failed topicals" is not sufficient. Specific language like "patient used clobetasol 0.05% ointment twice daily for 10 weeks with EASI score remaining at 32 (baseline 38)" is approvable.

Including Objective Disease Severity Scores

BCBSM and its pharmacy benefit manager (PBM) reviewers are trained to look for validated severity instruments. For atopic dermatitis, the IGA, EASI, and Peak Pruritus NRS are the most recognized. For asthma, include the ACT score, FEV1 percent predicted, and blood eosinophil count. For CRSwNP, include CT sinus staging (Lund-Mackay score) and prior surgical history if applicable. The NIH's National Institute of Arthritis and Musculoskeletal and Skin Diseases page on atopic dermatitis [12] and the NIH's National Heart, Lung, and Blood Institute asthma page [2] provide reference ranges your physician can cite.

Using Guideline-Based Language

The AAD's 2023 clinical guidelines state that dupilumab is recommended for adult patients with moderate-to-severe atopic dermatitis who are candidates for systemic therapy [1]. Quoting a named guideline by year and issuing body in the PA letter signals to reviewers that the prescribing physician is operating within the standard of care, not requesting off-label use.

The Endocrine Society's position papers on biologic access also address insurer obligation to cover FDA-approved biologics without undue barriers. See the Endocrine Society's advocacy resources at endocrine.org [13].

Special Situations: Pediatric Patients and Off-Label Use

Pediatric Coverage for Dupixent

FDA approved dupilumab for atopic dermatitis in children as young as 6 months in 2023 [14]. BCBSM commercial plans generally follow FDA label age thresholds for coverage. The pediatric Phase 3 trial (LIBERTY AD PRESCHOOL, N=162) showed 28% of children aged 6 months to 5 years achieved IGA 0/1 at week 16 with dupilumab versus 4% with placebo (P<0.001) [14]. The pediatric dupilumab trial on PubMed provides the clinical evidence supporting pediatric PAs [14].

Pediatric PAs require the child's current weight (dosing is weight-based below 60 kg), and the prescribing dermatologist or pediatric allergist should document severity using a pediatric-appropriate tool such as the Children's Dermatology Life Quality Index (CDLQI).

Off-Label Use

BCBSM does not routinely cover dupilumab for indications outside the FDA-approved list. Exceptions can exist if your physician provides compelling peer-reviewed literature and argues medical necessity through the appeals process. For now, off-label dupilumab coverage through BCBSM is not reliably achievable without extensive advocacy.

Formulary Verification: Confirm Before You Fill

BCBSM offers multiple plan types: PPO, HMO, POS, and Medicare Advantage. Formulary tiers and PA rules differ across plan types even within BCBSM. The only reliable way to confirm your specific plan's coverage is to:

1. Log in to the member portal at bcbsm.com and search the formulary for "dupilumab."
2. Call the member services number on the back of your insurance card and ask specifically: "Is dupilumab (Dupixent) covered under my plan, what tier is it on, what is my cost share after meeting my deductible, and is prior authorization required?"
3. Ask your pharmacy to run a test claim through the PBM (usually Prime Therapeutics for BCBSM commercial plans) before the prescription is written.

The FDA's drug database also allows verification that the indication you are seeking coverage for is listed in the current approved label: Dupixent on FDA Drugs@FDA [15].